<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hypertension after kidney transplantation</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hypertension after kidney transplantation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hypertension after kidney transplantation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John Vella, MD, FACP, FRCP, FASN, FAST</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel C Brennan, MD, FACP</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George L Bakris, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Deirdre Sawinski, MD, FAST</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hypertension is present in most patients with end-stage kidney disease (ESKD)/advanced chronic kidney disease (CKD). The blood pressure (BP) frequently rises early after kidney transplantation after <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> loading interacts with initial high-dose immunosuppression. Long-term BP is often easier to control after transplantation, as long as the glomerular filtration rate (GFR) improves into a good range. However, poorly controlled BP is common among kidney transplant recipients.</p><p>This topic will review the pathogenesis and risk factors, evaluation, and management of hypertension after kidney transplantation. A discussion of hypertension in nontransplant patients with acute and chronic kidney disease is presented separately. (See  <a class="medical medical_review" href="/z/d/html/3872.html" rel="external">"Overview of hypertension in acute and chronic kidney disease"</a>.)</p><p class="headingAnchor" id="H2485032376"><span class="h1">EPIDEMIOLOGY AND RISK FACTORS</span><span class="headingEndMark"> — </span>Hypertension is common among kidney transplant recipients, occurring in up to 85 percent of patients [<a href="#rid1">1-4</a>].</p><p>The following risk factors have been associated with a higher incidence of posttransplant hypertension [<a href="#rid1">1,4,5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Pretransplant hypertension</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated body mass index </p><p class="bulletIndent1"><span class="glyph">●</span>Male sex</p><p class="bulletIndent1"><span class="glyph">●</span>Older donor age</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of native kidneys</p><p class="bulletIndent1"><span class="glyph">●</span>Delayed and/or chronic allograft dysfunction</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a>, <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, and/or glucocorticoid therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Acute rejection</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrence of primary kidney disease in the allograft</p><p></p><p class="headingAnchor" id="H84195128"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Several factors may contribute to the pathogenesis of posttransplant hypertension among kidney transplant recipients, as discussed below.</p><p class="headingAnchor" id="H1555421599"><span class="h2">Allograft dysfunction</span><span class="headingEndMark"> — </span>Both acute and chronic injury to the kidney allograft can lead to posttransplant hypertension:</p><p class="bulletIndent1"><span class="glyph">●</span>Delayed graft function (DGF), defined as the need for dialysis within the first week posttransplant, can lead to volume overload and an acute elevation in blood pressure (BP) in the immediate posttransplant period. Removal of excess fluid with diuretics or dialysis will lower the BP in many cases. (See  <a class="medical medical_review" href="/z/d/html/7334.html" rel="external">"Kidney transplantation in adults: Timing of transplantation and issues related to dialysis", section on 'Dialysis immediately after transplantation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute rejection is frequently associated with hypertension. Hypertension in this setting is primarily due to sodium retention, increased activity of the renin-angiotensin system, and allograft dysfunction and is frequently compounded by treatment with high-dose glucocorticoids. Treatment and reversal of rejection will generally lower the BP.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic allograft injury (eg, due to chronic antibody-mediated rejection or interstitial fibrosis/tubular atrophy), thrombotic microangiopathy, or recurrent glomerular disease can also be associated with posttransplant hypertension. The mechanisms responsible for hypertension in these settings are similar to those involved in the pathogenesis of hypertension in patients with chronic kidney disease (CKD), as discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3872.html" rel="external">"Overview of hypertension in acute and chronic kidney disease", section on 'Chronic kidney disease'</a>.)</p><p></p><p class="headingAnchor" id="H3673353829"><span class="h2">Immunosuppressive agents</span><span class="headingEndMark"> — </span>Immunosuppressive agents, particularly glucocorticoids and calcineurin inhibitors (CNIs), play an important role in the development of posttransplant hypertension.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoids </strong>– Glucocorticoids are an important contributing factor to hypertension in the early posttransplant period, especially when higher doses are commonly used. However, because of rapid dose reduction, glucocorticoids are usually not a major risk factor for chronic hypertension in transplant recipients. However, discontinuation of glucocorticoid therapy among kidney transplant recipients receiving CNIs (ie, glucocorticoid withdrawal) has not been shown to significantly lower BP in the long term [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids", section on 'Cardiovascular effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Calcineurin inhibitors </strong>– CNIs play a predominant role in posttransplant hypertension if administered, raising the BP in almost all patients and producing overt hypertension in many cases [<a href="#rid7">7</a>]. Although BP is reportedly lower with <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> than with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> [<a href="#rid8">8</a>], the combination of <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> and tacrolimus can exacerbate underlying hypertension [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> acts by increasing both systemic and renal vascular (primarily affecting the afferent arteriole) resistance. How this occurs is incompletely understood. Increased release of vasoconstrictors, particularly endothelin, has been thought to play an important role [<a href="#rid10">10-12</a>]. Additional factors may include increased sodium transport in the loop of Henle [<a href="#rid13">13</a>]. <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">Tacrolimus</a> has been shown to cause hypertension by activation of the renal sodium chloride cotransporter [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus", section on 'Hypertension'</a>.)</p><p></p><p class="headingAnchor" id="H2310585512"><span class="h2">Transplant renal artery stenosis</span><span class="headingEndMark"> — </span>Kidney transplant renal artery stenosis (TRAS) is a potentially reversible cause of posttransplant hypertension, with an incidence ranging from 1 to 23 percent [<a href="#rid15">15</a>]. TRAS most commonly occurs at the site of the renal artery anastomosis but can also occur at the donor renal artery or feeding native artery. Flow limitation in the transplant renal artery can also be caused by surgical issues such as a vascular clamp, kinking, or angulation of the artery.</p><p>Although it can present at any time, TRAS usually becomes evident between three months and two years posttransplant [<a href="#rid16">16</a>]. Clinical features that should raise suspicion for the diagnosis of TRAS are similar to those that suggest renovascular disease among nontransplant patients  (<a class="graphic graphic_table graphicRef56130" href="/z/d/graphic/56130.html" rel="external">table 1</a>) and include the following [<a href="#rid17">17</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Worsening hypertension</p><p class="bulletIndent1"><span class="glyph">●</span>Hypokalemia (due to secondary hyperaldosteronism)</p><p class="bulletIndent1"><span class="glyph">●</span>Decline in kidney function in the setting of treatment with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) (see  <a class="medical medical_review" href="/z/d/html/3873.html" rel="external">"Renal effects of ACE inhibitors in hypertension"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Episodes of flash pulmonary edema</p><p class="bulletIndent1"><span class="glyph">●</span>An abdominal bruit over the allograft (may or may not be present) </p><p></p><p>The risk factors for TRAS include difficulties in organ procurement and operative techniques (such as improper suturing and trauma), atherosclerotic disease, cytomegalovirus infection, and delayed allograft function [<a href="#rid15">15,18,19</a>].</p><p>The evaluation and management of TRAS are discussed below. (See <a class="local">'Evaluation for transplant renal artery stenosis'</a> below and <a class="local">'Evaluation of new-onset or worsening hypertension'</a> below and <a class="local">'Management of transplant renal artery stenosis'</a> below.)</p><p class="headingAnchor" id="H203687983"><span class="h2">Donor characteristics</span><span class="headingEndMark"> — </span>There is suggestive evidence that the transplanted kidney may have prohypertensive or antihypertensive properties. Multiple cross-transplantation studies in experimental models of genetic hypertension have shown that the inherited tendency to hypertension resides primarily in the kidney [<a href="#rid20">20</a>]. A similar relationship may exist in humans. In one report of six transplant recipients with a prior history of end-stage kidney disease (ESKD) due to hypertensive nephrosclerosis and resistant hypertension while on dialysis, transplantation of a kidney from normotensive donors with a negative family history of hypertension led to correction of primary hypertension [<a href="#rid21">21</a>].</p><p>A larger study of 85 patients found that elevations in BP and increased antihypertensive drug requirements occurred much more frequently in recipients from "normotensive" families who received a kidney from a donor with a "hypertensive family"; a family history of hypertension in the recipient blunted the effect of a "hypertensive" kidney [<a href="#rid22">22</a>]. A follow-up study found that a "hypertensive" kidney transplanted into a recipient from a "normotensive" family had a greater hypertensive response during an acute rejection episode than did all other donor-recipient combinations [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H147950156"><span class="h1">EVALUATION</span></p><p class="headingAnchor" id="H4175826637"><span class="h2">Routine blood pressure monitoring after transplant</span><span class="headingEndMark"> — </span>Following hospital discharge, blood pressure (BP) is routinely monitored at each visit to the transplant clinic using standardized office-based BP measurements. At our centers, the initial BP measurement is obtained using an automated device; if elevated, we repeat with a manual BP measurement towards the end of the visit when the patient has been seated at rest. In patients with diabetes, on alpha blocker therapy, or with postural symptoms, we perform supine, sitting, and standing BPs to assess for orthostatic hypotension. The goal BP for kidney transplant recipients is discussed below. (See <a class="local">'Blood pressure goal'</a> below.)</p><p>We advise all kidney transplant recipients to self-measure their BP at home, at least daily for the first three months posttransplant and then, at a minimum, when they have routine laboratory monitoring. We review optimal home BP monitoring technique with patients at posttransplant clinic visits. </p><p>We do not routinely perform 24-hour ambulatory BP measurements (ABPMs) in kidney transplant recipients. However, ABPMs may be helpful for patients who have resistant hypertension or suspected white coat hypertension [<a href="#rid24">24</a>].</p><p>A more detailed discussion of in-office and out-of-office BP measurement is presented separately. (See  <a class="medical medical_review" href="/z/d/html/3879.html" rel="external">"Blood pressure measurement in the diagnosis and management of hypertension in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3820.html" rel="external">"Out-of-office blood pressure measurement: Ambulatory and self-measured blood pressure monitoring"</a>.)</p><p class="headingAnchor" id="H3811267708"><span class="h2">Evaluation of new-onset or worsening hypertension</span><span class="headingEndMark"> — </span>All kidney transplant recipients with new-onset or worsening hypertension after transplantation should be evaluated for potentially reversible causes. We take the following approach:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assess volume status </strong>– We assess all patients for symptoms or signs of volume overload. Volume overload is a common cause of elevated BP in the immediate posttransplant period but may also be present later in patients with allograft dysfunction and sodium retention.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assess allograft function </strong>– We assess kidney allograft function by obtaining a serum creatinine level and a spot urine protein-to-creatinine ratio. Both acute and chronic allograft dysfunction can be causes of posttransplant hypertension. The evaluation and diagnosis of acute and chronic allograft dysfunction are presented in detail separately. (See <a class="local">'Allograft dysfunction'</a> above and  <a class="medical medical_review" href="/z/d/html/7301.html" rel="external">"Kidney transplantation in adults: Evaluation and diagnosis of acute kidney allograft dysfunction"</a> and  <a class="medical medical_review" href="/z/d/html/7359.html" rel="external">"Kidney transplantation in adults: Chronic allograft nephropathy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assess immunosuppression regimen </strong>– We assess the patient's maintenance immunosuppression regimen, in particular the doses and trends in levels of the calcineurin inhibitor (CNI) and oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>. (See <a class="local">'Immunosuppressive agents'</a> above and <a class="local">'Management of immunosuppression'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluate selected patients for transplant renal artery stenosis</strong> – If the patient has clinical features that are suggestive of transplant renal artery stenosis (TRAS), we evaluate for TRAS, as discussed below. (See <a class="local">'Transplant renal artery stenosis'</a> above and <a class="local">'Evaluation for transplant renal artery stenosis'</a> below.)</p><p></p><p class="headingAnchor" id="H1742978546"><span class="h2">Evaluation for transplant renal artery stenosis</span><span class="headingEndMark"> — </span>Indications for testing for TRAS vary among transplant centers. At our centers, we perform an evaluation for TRAS in patients with new-onset or worsening hypertension who have clinical features suggestive of TRAS, as well as all patients with resistant hypertension. Some, but not all, transplant centers routinely evaluate all kidney transplant recipients for TRAS as part of posttransplant care. (See <a class="local">'Evaluation of new-onset or worsening hypertension'</a> above and <a class="local">'Resistant hypertension'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of test </strong>– Reasonable noninvasive modalities for initial testing include duplex Doppler ultrasonography, computed tomographic angiography (CTA), and magnetic resonance angiography (MRA). The choice of test should be based upon institutional expertise and patient factors. At many centers, including ours, duplex Doppler ultrasonography is the preferred initial diagnostic test for TRAS. If Doppler ultrasonography findings are consistent with TRAS, some centers will confirm the findings with either CTA or MRA, while others will proceed directly to renal arteriography. If the noninvasive test is inconclusive and the clinical suspicion remains high, we often proceed with arteriography. (See <a class="local">'Management of transplant renal artery stenosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Testing options</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duplex Doppler ultrasonography </strong>– Duplex Doppler ultrasonography is highly accurate but also highly dependent upon the experience of the ultrasonographer [<a href="#rid25">25,26</a>]. The following findings are used to establish a diagnosis of TRAS [<a href="#rid27">27</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Peak systolic velocity in the transplant renal artery &gt;200 cm/second</p><p class="bulletIndent3"><span class="glyph">-</span>Acceleration time in the transplant renal and intrarenal arteries ≥0.1 second</p><p class="bulletIndent3"><span class="glyph">-</span>Ratio of peak systolic velocity in the transplant renal artery to external iliac arteries &gt;1.8</p><p class="bulletIndent3"><span class="glyph">-</span>Presence of tardus parvus waveform</p><p></p><p class="bulletIndent2">Reported sensitivities of Doppler ultrasonography for the diagnosis of TRAS range from 58 to 100 percent, while specificity ranges from 87 to 100 percent [<a href="#rid26">26,28-31</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Spiral CT scan with CT angiography </strong>– Spiral CTA is another accurate noninvasive test that can be used for diagnosing TRAS [<a href="#rid32">32,33</a>]. CTA is less operator dependent than ultrasonography and uses a lower volume of intravenous contrast than arteriography. (See  <a class="medical medical_review" href="/z/d/html/3825.html" rel="external">"Establishing the diagnosis of renovascular hypertension", section on 'Spiral CT scan with CT angiography'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Magnetic resonance angiography </strong>– As in the nontransplant population, MRA can be used to evaluate for renal artery stenosis among transplant recipients [<a href="#rid34">34,35</a>]. Technical improvements have resulted in enhanced detection of significant renal artery disease. In small studies, three-dimensional gadolinium-enhanced MRA has demonstrated a sensitivity of 100 percent and specificity of 75 to 98 percent in detecting stenosis greater than 50 percent [<a href="#rid36">36-41</a>]. </p><p></p><p class="bulletIndent2">The administration of gadolinium during MR imaging has been strongly linked to an often-severe disease called nephrogenic systemic fibrosis among patients with moderate to severe kidney disease, particularly those requiring dialysis. In general, gadolinium-based contrast agents can be given safely without concern to patients with an estimated glomerular filtration rate (eGFR) between 30 to 59 mL/min/1.73 m<sup>2</sup>. Gadolinium-based imaging should be avoided, if possible, in patients with an eGFR &lt;30 mL/min/1.73 m<sup>2</sup>, acute kidney injury, or on dialysis. The appropriate use of gadolinium-based contrast agents in patients with kidney function impairment is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/113082.html" rel="external">"Patient evaluation before gadolinium contrast administration for magnetic resonance imaging", section on 'Approach to preventing nephrogenic systemic fibrosis'</a>.)  </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Renal arteriography </strong>– Renal arteriography is the gold standard for establishing the diagnosis of TRAS. Given its invasive nature, it is not commonly used as an initial diagnostic test for TRAS. Its use is generally reserved for patients with inconclusive results on noninvasive testing or patients with established TRAS who require treatment. Digital subtraction angiography is generally preferred over conventional angiography because of its need for less contrast. An alternative modality is carbon dioxide (CO2) angiography, which uses CO2 as a contrast agent, enabling its use in patients with kidney function impairment.</p><p></p><p class="bulletIndent2">Some clinicians perform a kidney allograft biopsy prior to angiography to rule out chronic rejection or other forms of kidney parenchymal disease. These findings decrease the likelihood of a successful response to correction of a stenosis and may be relative contraindications to intervention [<a href="#rid42">42</a>]. </p><p></p><p class="headingAnchor" id="H1686791887"><span class="h1">MANAGEMENT OF POSTTRANSPLANT HYPERTENSION</span></p><p class="headingAnchor" id="H2529907204"><span class="h2">Rationale for treatment</span><span class="headingEndMark"> — </span>Posttransplant hypertension should be treated to protect against cardiovascular disease and possible hypertensive injury to the graft. Elevated blood pressure (BP) and pulse pressure can result in left ventricular hypertrophy, which is an independent risk factor for heart failure and death in the general population and kidney transplant recipients [<a href="#rid43">43-47</a>]. Posttransplant hypertension has also been associated with decreased long-term kidney allograft survival [<a href="#rid45">45,46,48,49</a>]. There is experimental evidence to support this hypothesis. In an animal model of chronic kidney allograft rejection, antihypertensive therapy improved graft survival and function, diminished glomerular injury, and reduced proteinuria [<a href="#rid50">50</a>]. </p><p>There are also clinical data showing benefits with BP control. This was best shown in a study of nearly 25,000 first deceased-donor kidney recipients [<a href="#rid51">51</a>]. Among patients with systolic BPs &gt;140 mmHg at one year posttransplant, improved long-term allograft outcome was observed among patients with systolic pressures controlled to less than 140 mmHg at three years versus those with sustained increases in systolic pressure (relative risk [RR] 0.79, 95% CI 0.73-0.86).</p><p class="headingAnchor" id="H3260003628"><span class="h2">Patients in the immediate posttransplant period</span><span class="headingEndMark"> — </span>Hypertension in the immediate posttransplant period (ie, within the first week posttransplant) is usually associated with volume overload and/or graft dysfunction due to rejection, ischemia, or calcineurin inhibitor toxicity, although pain and anxiety may also be contributing factors. Reversal of rejection or removal of excess fluid with diuretics or dialysis will lower the BP in many cases. (See <a class="local">'Pathogenesis'</a> above.)</p><p>In the immediate posttransplant period, it is important to maintain adequate organ perfusion to avoid hypotension and the risk of graft thrombosis. However, there is no evidence to guide the optimal BP target in this setting, and practice varies among transplant centers. Some UpToDate authors of this topic allow higher BP levels (ie, "permissive hypertension") and target a BP of less than 160/90 mmHg in the first one to two weeks posttransplant, whereas other authors would target a lower BP goal (eg, less than 140/90). However, there are no data to support these or any other BP thresholds for patients in the immediate posttransplant period.</p><p>In patients who had pharmacologically treated hypertension prior to transplant, we generally resume their antihypertensive medications after transplant surgery, with the exception of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). We generally hold ACE inhibitors and ARBs for the first three to six months posttransplantation since these medications can cause an increase in serum creatinine concentration, cause hyperkalemia, and prevent recovery from anemia. This is discussed in more detail below. (See <a class="local">'Additional agents for uncontrolled hypertension'</a> below.)</p><p class="headingAnchor" id="H3956336473"><span class="h2">Patients in the later posttransplant period</span><span class="headingEndMark"> — </span>Our general approach to posttransplant hypertension in patients beyond the immediate posttransplant period is discussed below.</p><p class="headingAnchor" id="H994531853"><span class="h3">Blood pressure goal</span><span class="headingEndMark"> — </span>The optimal long-term BP goal for kidney transplant recipients is unclear. We suggest a target BP of &lt;130/80 mmHg using properly measured BP. The following are options for properly measuring BP: standardized office-based measurement  (<a class="graphic graphic_table graphicRef115862" href="/z/d/graphic/115862.html" rel="external">table 2</a>), automated oscillometric BP monitoring, home BP, and ambulatory BP monitoring (ABPM). (See  <a class="medical medical_review" href="/z/d/html/3879.html" rel="external">"Blood pressure measurement in the diagnosis and management of hypertension in adults", section on 'Selecting a measurement strategy'</a>.)</p><p>"Casual" or "routine" BP measurement, which is commonly performed in the clinical setting, provides unreliable readings and should not be used. On average, casual measurements lead to BP readings that are 5 to 10 mmHg higher than readings obtained with proper technique, although there is a large degree of interindividual variability. </p><p>Our approach is largely consistent with the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines [<a href="#rid52">52,53</a>]. This BP target is higher than that recommended for nontransplant patients with chronic kidney disease (CKD). The different types of BP measurement are defined and discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension", section on 'Patients with chronic kidney disease'</a>.)</p><p>There is no high-quality evidence to support this or any other BP target in kidney transplant recipients. There are no data from randomized trials in kidney transplant recipients evaluating the effects of different BP targets on patient-relevant outcomes such as mortality, cardiovascular events, or allograft survival. In the absence of evidence to guide optimal BP, BP targets in kidney transplant recipients have historically been adopted from those for higher-risk populations, such as patients with CKD, diabetes mellitus, or atherosclerotic cardiovascular disease. (See  <a class="medical medical_review" href="/z/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension"</a>.)</p><p>There are two main reasons to explain the discrepancy between the recommended BP targets for kidney transplant recipients and nontransplant patients with CKD. First is the exclusion of kidney transplant recipients from major randomized trials (such as The Systolic Blood Pressure Intervention Trial [SPRINT]) that found lower rates of fatal and nonfatal major cardiovascular events and death from any cause in patients assigned to more intensive BP lowering. Secondly, there are concerns about the modestly higher risk of acute kidney injury (AKI) and decline in estimated glomerular filtration rate (eGFR) among patients assigned to a systolic BP of less than 120 mmHg compared with those assigned to a target of less than 140 mmHg in the SPRINT trial. Denervation of the transplanted kidney and treatment with a calcineurin inhibitor (CNI) to prevent rejection may render the allograft less capable of autoregulation and increase its susceptibility to AKI and loss of eGFR with lower BP targets. However, there are no clinical data to support this hypothesis, and studies in kidney transplant recipients have not identified a BP threshold below which there is a higher risk of graft failure or eGFR decline [<a href="#rid54">54</a>]. The SPRINT trial is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension"</a>.)</p><p class="headingAnchor" id="H2466919243"><span class="h3">Management of immunosuppression</span><span class="headingEndMark"> — </span>For patients with posttransplant hypertension, some UpToDate contributors to this topic decrease the CNI (<a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> or <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>) to the lowest effective dose needed to prevent acute rejection, as determined by clinical judgment, while others do not adjust immunosuppression doses in response to hypertension. We do not discontinue a CNI purely for posttransplant hypertension. (See <a class="local">'Immunosuppressive agents'</a> above.) </p><p>In patients receiving low-dose <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> as part of their maintenance immunosuppression, we do not discontinue prednisone for posttransplant hypertension. Discontinuation of glucocorticoid therapy among kidney transplant recipients receiving CNIs has not been shown to significantly lower BP [<a href="#rid6">6</a>]. For patients in whom higher doses of prednisone (eg, for the treatment of rejection) are likely contributing to posttransplant hypertension, we adjust BP medications as needed to control hypertension while tapering prednisone as indicated.</p><p class="headingAnchor" id="H2519650035"><span class="h3">Nonpharmacologic therapy for all patients</span><span class="headingEndMark"> — </span>Similar to the treatment of hypertension in the general population, the treatment of posttransplant hypertension involves nonpharmacologic therapy (also called lifestyle modification)  (<a class="graphic graphic_table graphicRef116041" href="/z/d/graphic/116041.html" rel="external">table 3</a>) alone or in concert with antihypertensive drug therapy. Although these lifestyle modifications have not been well studied in kidney transplant recipients [<a href="#rid55">55-58</a>], they have been shown to have beneficial effects on lowering BP in the general population. These measures are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3852.html" rel="external">"Overview of hypertension in adults", section on 'Nonpharmacologic therapy'</a>.)</p><p class="headingAnchor" id="H83427820"><span class="h3">Approach to pharmacologic therapy</span><span class="headingEndMark"> — </span>Most transplant recipients with posttransplant hypertension will require pharmacologic antihypertensive therapy to achieve the goal BP. </p><p class="headingAnchor" id="H3473694410"><span class="h4">Patients with new-onset hypertension</span><span class="headingEndMark"> — </span>In patients with new-onset posttransplant hypertension who are not on antihypertensive therapy, our approach is discussed below.</p><p class="headingAnchor" id="H3784983468"><span class="h5">Calcium channel blockers as first-line therapy</span><span class="headingEndMark"> — </span>For most kidney transplant recipients, we suggest a dihydropyridine calcium channel blocker (eg, <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">amlodipine</a>, <a class="drug drug_general" data-topicid="8438" href="/z/d/drug information/8438.html" rel="external">felodipine</a>, <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">nifedipine</a> [preferably long-acting]) as first-line antihypertensive therapy rather than other antihypertensive agents. Dihydropyridine calcium channel blockers have been shown to reduce the risk of graft loss [<a href="#rid59">59</a>] and minimize CNI-induced vasoconstriction.</p><p>We generally <strong>avoid</strong> nondihydropyridine calcium channel blockers (eg, <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a>, <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a>) since they are potent cytochrome inhibitors (CYP3A/4) and concurrent use with CNIs (<a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> or <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>) or mammalian (mechanistic) target of rapamycin (mTOR) inhibitors (<a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> or <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>) will lead to elevated immunosuppressive drug levels. If these agents are used, frequently measuring CNI or mTOR inhibitor levels before and after such medication transitions is necessary. Some transplant centers preferentially use nondihydropyridine calcium channel blockers in recipients who are rapid CNI drug metabolizers to limit the CNI dose and control hypertension.</p><p>Several studies have evaluated the efficacy of calcium channel blockers in kidney transplant patients [<a href="#rid2">2,59-65</a>]. A 2009 systematic review of 29 randomized trials with 2262 patients that compared calcium channel blockers with placebo or no treatment, as well as seven randomized trials with 405 patients that compared calcium channel blockers with ACE inhibitors, reported the following findings [<a href="#rid59">59</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Compared with placebo or no treatment, calcium channel blockers reduced the risk of allograft loss (RR 0.75, 95% CI 0.59-0.99) and improved GFR (mean difference of 4.45 mL/min, 95% CI 2.22-6.68).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Compared with calcium channel blockers, ACE inhibitors reduced GFR (mean difference of 11.48 mL/min, 95% CI -5.75 to -7.21) and increased the risk of hyperkalemia (RR 3.76, 95% CI 1.89-7.43).</p><p></p><p class="headingAnchor" id="H4002447247"><span class="h5">Additional agents for uncontrolled hypertension</span><span class="headingEndMark"> — </span>If BP is not controlled with a calcium channel blocker, other antihypertensive drugs can be added as necessary. There are no classes of antihypertensive medications that are contraindicated in kidney transplant recipients, and ACE inhibitors/ARBs, beta blockers, diuretics, and alpha blockers all may be effective in this setting. The choice of second-line agent is generally guided by patient comorbidities and time after transplant. Special considerations in kidney transplant recipients include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diuretics </strong>– Thiazide-like (eg, <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">chlorthalidone</a>, <a class="drug drug_general" data-topicid="8557" href="/z/d/drug information/8557.html" rel="external">indapamide</a>) or thiazide-type (eg, <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">hydrochlorothiazide</a>) diuretics may be useful for patients with edema and hyperkalemia. A diuretic may also be necessary in patients with allograft dysfunction in whom volume expansion often contributes to the rise in BP. (See <a class="local">'Allograft dysfunction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ACE inhibitors and ARBs –</strong> ACE inhibitors and ARBs may be useful in patients with proteinuria. Some experts prefer to wait three to six months posttransplant before starting an ACE inhibitor or ARB, given the concern that concomitant use of these agents with CNIs in the early posttransplant period could cause hyperkalemia or an increase in the serum creatinine level that might confound the ability to accurately detect acute rejection. However, studies have shown that ACE inhibitors and ARBs are generally safe when used in the early posttransplant period, suggesting that initiation of these agents need not be deferred [<a href="#rid66">66,67</a>]. </p><p></p><p class="bulletIndent1">Several studies have evaluated the efficacy and safety of ACE inhibitors and ARBs in kidney transplant recipients [<a href="#rid59">59,63,68-76</a>]. However, clear evidence showing a kidney or mortality benefit with these agents is lacking. As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The efficacy and safety of ACE inhibitors and ARBs in kidney transplant recipients were evaluated in a 2009 systematic review of 10 trials (445 patients) that compared ACE inhibitors with placebo or no treatment and seven trials (405 patients) that compared ACE inhibitors with calcium channel blockers [<a href="#rid59">59</a>]. Compared with calcium channel blockers, ACE inhibitors were associated with a decrease in GFR (mean difference of 11.48 mL/min, 95% CI -5.75 to -7.21), proteinuria level (mean difference of -0.28 g/24 hours, 95% CI -0.47 to -0.10), and hemoglobin value (mean difference of -1.3 g/dL, 95% CI -.57 to -1.02), and an increased incidence of hyperkalemia (RR 3.76, 95% CI 1.89-7.43). No definitive conclusions with respect to GFR and allograft loss could be reached when ACE inhibitors were compared with placebo or no treatment.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a subsequent trial that randomly assigned 154 kidney transplant recipients within three months of transplant to <a class="drug drug_general" data-topicid="9574" href="/z/d/drug information/9574.html" rel="external">losartan</a> 100 mg or placebo, rates of the composite outcome (graft loss due to biopsy-proven interstitial fibrosis/tubular atrophy or a doubling of the fraction of renal cortical volume occupied by interstitium at five years) were lower in the losartan group (13 versus 27 percent), but this difference was not statistically significant [<a href="#rid73">73</a>]. There was no difference in the time to end-stage kidney disease (ESKD) or death between the groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta blockers </strong>– Beta blockers (eg, <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">atenolol</a>, <a class="drug drug_general" data-topicid="9158" href="/z/d/drug information/9158.html" rel="external">bisoprolol</a>, <a class="drug drug_general" data-topicid="9208" href="/z/d/drug information/9208.html" rel="external">carvedilol</a>, <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a>) may be indicated in transplant recipients with known atherosclerotic cardiovascular disease, although data on their efficacy and safety in this patient population are limited. Although use of beta blockers in kidney transplant recipients has increased over time, it may still be suboptimal [<a href="#rid77">77</a>]. Like ACE inhibitors and ARBs, beta blockers are a common cause of hyperkalemia after transplantation [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alpha blockers </strong>– Alpha blockers (eg, <a class="drug drug_general" data-topicid="9389" href="/z/d/drug information/9389.html" rel="external">doxazosin</a>, <a class="drug drug_general" data-topicid="9806" href="/z/d/drug information/9806.html" rel="external">prazosin</a>) may be useful in patients with benign prostatic hyperplasia and lower urinary tract symptoms. However, alpha blockers should be avoided in patients with orthostatic hypotension. (See  <a class="medical medical_review" href="/z/d/html/3869.html" rel="external">"Choice of drug therapy in primary (essential) hypertension", section on 'Patients with orthostatic hypotension'</a>.)</p><p></p><p class="headingAnchor" id="H706530496"><span class="h4">Patients already on antihypertensive therapy</span><span class="headingEndMark"> — </span>Patients with a history of hypertension prior to transplant generally experience an improvement in BP after transplantation that is commensurate with the degree of kidney function acquired from the allograft. However, most patients will still require antihypertensive medications for BP control. Our approach in such patients is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood pressure well controlled </strong>– Patients whose BP is well controlled on their antihypertensive regimen can generally continue their regimen without any modifications. Some patients, particularly those who are younger, may require fewer or even no antihypertensive medications. If the patient is not already taking a dihydropyridine calcium channel blocker, some clinicians may choose to substitute one of their medications with this agent given its potential benefits in transplant recipients. (See <a class="local">'Calcium channel blockers as first-line therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood pressure not well controlled </strong>– For patients whose BP is not at the desired target on their antihypertensive regimen, additional antihypertensive medications can be added as necessary. Our approach to selecting an agent in such patients is similar to that for transplant recipients with new-onset hypertension, as discussed above. (See <a class="local">'Patients with new-onset hypertension'</a> above.)</p><p></p><p class="headingAnchor" id="H1777591570"><span class="h3">Resistant hypertension</span><span class="headingEndMark"> — </span>Resistant hypertension is defined as BP that remains above goal in spite of concurrent use of three antihypertensive agents or BP that is controlled with four or more medications. One of the medications should be a diuretic, if tolerated, and all should be prescribed at maximum recommended (or maximally tolerated) antihypertensive doses. (See  <a class="medical medical_review" href="/z/d/html/3818.html" rel="external">"Definition, risk factors, and evaluation of resistant hypertension"</a>.)</p><p>Kidney transplant recipients with resistant hypertension should undergo an evaluation to exclude transplant renal artery stenosis, unless there are findings (such as kidney function impairment and an active urine sediment) suggesting possible recurrence of the primary disease (see <a class="local">'Evaluation for transplant renal artery stenosis'</a> above). Angioplasty (with or without stenting) or surgery are indicated if a significant stenosis is found. In the absence of renovascular disease, recurrent disease, or rejection, consideration should be given to removal of the native kidneys if there is no other way to control the hypertension [<a href="#rid79">79,80</a>]. (See <a class="local">'Management of transplant renal artery stenosis'</a> below.)</p><p class="headingAnchor" id="H3264400357"><span class="h1">MANAGEMENT OF TRANSPLANT RENAL ARTERY STENOSIS</span><span class="headingEndMark"> — </span>Our general approach to the management of transplant renal artery stenosis (TRAS) is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medical therapy </strong>– All kidney transplant recipients with an established diagnosis of TRAS should receive nonpharmacologic and pharmacologic therapy for control of hypertension, as discussed elsewhere in this topic. (See <a class="local">'Nonpharmacologic therapy for all patients'</a> above and <a class="local">'Approach to pharmacologic therapy'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for revascularization </strong>– In transplant recipients with established TRAS, indications for revascularization include failure of optimal medical therapy to control blood pressure (BP), intolerance to optimal medical therapy (eg, deterioration of kidney function during antihypertensive drug therapy), recurrent flash pulmonary edema, or otherwise unexplained worsening graft function. These indications are similar to those for nontransplant patients who have bilateral renal artery stenosis or unilateral stenosis to a solitary functioning kidney, as discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3836.html" rel="external">"Treatment of bilateral atherosclerotic renal artery stenosis or stenosis to a solitary functioning kidney", section on 'General approach to therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of intervention </strong>– In transplant recipients who are selected for revascularization, percutaneous balloon angioplasty (with or without stenting) is most commonly performed. Surgical revascularization is generally reserved for patients with resistant hypertension or with proximal recipient arteriosclerotic disease since the extensive fibrosis and scarring around the transplanted kidney make surgical correction of TRAS difficult. </p><p></p><p class="bulletIndent1">Percutaneous balloon angioplasty may be technically successful in up to 80 percent of cases, although 20 percent will develop recurrent stenosis [<a href="#rid42">42,81</a>]. This technique is also less successful in the patient with arterial kinking, anastomotic structures, and long lesions [<a href="#rid82">82</a>]. Repeat angioplasty is usually not successful in such patients.</p><p></p><p class="bulletIndent1">The success of stent placement used in combination with angioplasty for a wide variety of vascular lesions suggests that deployment of metallic stents may be useful [<a href="#rid83">83,84</a>], particularly in those with recurrent TRAS [<a href="#rid85">85,86</a>]. Stent deployment in six consecutive patients with recurrent stenosis was evaluated in a retrospective study [<a href="#rid85">85</a>]. At almost three years postprocedure, all arteries were patent without significant stenosis, and no additional interventions were required. (See  <a class="medical medical_review" href="/z/d/html/3836.html" rel="external">"Treatment of bilateral atherosclerotic renal artery stenosis or stenosis to a solitary functioning kidney", section on 'Stent placement'</a>.)</p><p></p><p class="bulletIndent1">Success rates of surgical revascularization have ranged from 60 to 90 percent. However, recurrent stenosis may occur in approximately 10 percent, and graft loss has been reported in up to 30 percent of cases [<a href="#rid82">82,87</a>].</p><p></p><p class="headingAnchor" id="H991142997"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110754.html" rel="external">"Society guideline links: Kidney transplantation"</a>.)</p><p class="headingAnchor" id="H23739452"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology and pathogenesis </strong>– Hypertension is common among kidney transplant recipients, occurring in up to 85 percent of patients. Several factors may contribute to the pathogenesis of posttransplant hypertension, including allograft dysfunction, immunosuppressive agents, transplant renal artery stenosis (TRAS), and certain donor characteristics. (See <a class="local">'Epidemiology and risk factors'</a> above and <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Routine monitoring after transplant </strong>–<strong> </strong>Blood pressure (BP) is routinely monitored at each visit to the transplant clinic using office-based BP measurements. We advise all kidney transplant recipients to self-measure their BP at home, at least daily for the first three months posttransplant and then, at a minimum, when they have routine laboratory monitoring. (See <a class="local">'Routine blood pressure monitoring after transplant'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Evaluation of new-onset or worsening hypertension </strong>– All kidney transplant recipients with new-onset or worsening hypertension after transplantation should be evaluated for potentially reversible causes. We assess volume status, allograft function, and the immunosuppression regimen. Patients with clinical features suggestive of TRAS should be evaluated for TRAS. (See <a class="local">'Evaluation of new-onset or worsening hypertension'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Evaluation for TRAS </strong>– Indications for testing for TRAS vary among transplant centers. We evaluate for TRAS in patients with new-onset or worsening hypertension who have clinical features suggestive of TRAS, as well as all patients with resistant hypertension. Reasonable noninvasive modalities for initial testing include duplex Doppler ultrasonography, computed tomographic angiography (CTA), and magnetic resonance angiography (MRA). The choice of test should be based upon institutional expertise and patient factors. (See <a class="local">'Evaluation for transplant renal artery stenosis'</a> above and <a class="local">'Resistant hypertension'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of posttransplant hypertension </strong>–<strong> </strong>Posttransplant hypertension should be treated to protect against cardiovascular disease and possible hypertensive injury to the graft. (See <a class="local">'Rationale for treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immediate posttransplant period</strong> – In the first week posttransplant, it is important to maintain adequate organ perfusion to avoid hypotension and the risk of graft thrombosis. However, there is no evidence to guide the optimal BP target in this setting, and practice varies among transplant centers. Some UpToDate authors of this topic allow higher BP levels (ie, "permissive hypertension") and target a BP of less than 160/90 mmHg in the first one to two weeks posttransplant, whereas other authors would target a lower BP goal (eg, less than 140/90). (See <a class="local">'Patients in the immediate posttransplant period'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Later posttransplant period </strong>– Our general approach to posttransplant hypertension in patients beyond the immediate posttransplant period is as follows:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>BP goal </strong>– The optimal long-term BP goal for kidney transplant recipients is unclear. For kidney transplant recipients, we suggest a target BP of less than 130/80 mmHg rather than lower targets (which are recommended for other patients with chronic kidney disease [CKD]) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The following are options for properly measuring BP to determine if a patient is at goal: standardized office-based measurement  (<a class="graphic graphic_table graphicRef115862" href="/z/d/graphic/115862.html" rel="external">table 2</a>), automated oscillometric BP monitoring, home BP, and ambulatory BP monitoring [ABPM]). "Casual" or "routine" BP measurement, which is commonly performed in the clinical setting, provides unreliable readings. Our approach is largely consistent with the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. (See <a class="local">'Blood pressure goal'</a> above.) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Nonpharmacologic therapy </strong>– Similar to the treatment of hypertension in the general population, the treatment of posttransplant hypertension involves nonpharmacologic therapy (also called lifestyle modification)  (<a class="graphic graphic_table graphicRef116041" href="/z/d/graphic/116041.html" rel="external">table 3</a>) alone or in concert with antihypertensive drug therapy. (See <a class="local">'Nonpharmacologic therapy for all patients'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Pharmacologic therapy </strong>– For most kidney transplant recipients with new-onset posttransplant hypertension who are not on antihypertensive therapy, we suggest a dihydropyridine calcium channel blocker as first-line antihypertensive therapy rather than other antihypertensive agents (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Approach to pharmacologic therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of TRAS </strong>– Indications for revascularization of TRAS include failure of optimal medical therapy to control BP, intolerance to optimal medical therapy, recurrent flash pulmonary edema, or otherwise unexplained worsening graft function. In patients selected for revascularization, percutaneous balloon angioplasty (with or without stenting) is most commonly performed. Surgical revascularization is generally reserved for patients with resistant hypertension or proximal recipient arteriosclerotic disease. (See <a class="local">'Management of transplant renal artery stenosis'</a> above.) </p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplantation. Am J Kidney Dis 2004; 43:1071.</a></li><li><a class="nounderline abstract_t">Ponticelli C, Montagnino G, Aroldi A, et al. Hypertension after renal transplantation. Am J Kidney Dis 1993; 21:73.</a></li><li><a class="nounderline abstract_t">Budde K, Waiser J, Fritsche L, et al. Hypertension in patients after renal transplantation. Transplant Proc 1997; 29:209.</a></li><li><a class="nounderline abstract_t">Campistol JM, Romero R, Paul J, Gutiérrez-Dalmau A. Epidemiology of arterial hypertension in renal transplant patients: changes over the last decade. Nephrol Dial Transplant 2004; 19 Suppl 3:iii62.</a></li><li><a class="nounderline abstract_t">Pérez Fontán M, Rodríguez-Carmona A, García Falcón T, et al. Early immunologic and nonimmunologic predictors of arterial hypertension after renal transplantation. Am J Kidney Dis 1999; 33:21.</a></li><li><a class="nounderline abstract_t">Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248:564.</a></li><li><a class="nounderline abstract_t">Textor SC, Canzanello VJ, Taler SJ, et al. Cyclosporine-induced hypertension after transplantation. Mayo Clin Proc 1994; 69:1182.</a></li><li><a class="nounderline abstract_t">Margreiter R, European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002; 359:741.</a></li><li><a class="nounderline abstract_t">Gonwa T, Mendez R, Yang HC, et al. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Transplantation 2003; 75:1213.</a></li><li><a class="nounderline abstract_t">Watschinger B, Sayegh MH. Endothelin in organ transplantation. Am J Kidney Dis 1996; 27:151.</a></li><li><a class="nounderline abstract_t">Perico N, Ruggenenti P, Gaspari F, et al. Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation. Transplantation 1992; 54:56.</a></li><li><a class="nounderline abstract_t">Takeda Y, Miyamori I, Wu P, et al. Effects of an endothelin receptor antagonist in rats with cyclosporine-induced hypertension. Hypertension 1995; 26:932.</a></li><li><a class="nounderline abstract_t">Esteva-Font C, Ars E, Guillen-Gomez E, et al. Ciclosporin-induced hypertension is associated with increased sodium transporter of the loop of Henle (NKCC2). Nephrol Dial Transplant 2007; 22:2810.</a></li><li><a class="nounderline abstract_t">Hoorn EJ, Walsh SB, McCormick JA, et al. The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nat Med 2011; 17:1304.</a></li><li><a class="nounderline abstract_t">Audard V, Matignon M, Hemery F, et al. Risk factors and long-term outcome of transplant renal artery stenosis in adult recipients after treatment by percutaneous transluminal angioplasty. Am J Transplant 2006; 6:95.</a></li><li><a class="nounderline abstract_t">Bruno S, Remuzzi G, Ruggenenti P. Transplant renal artery stenosis. J Am Soc Nephrol 2004; 15:134.</a></li><li><a class="nounderline abstract_t">Voiculescu A, Schmitz M, Hollenbeck M, et al. Management of arterial stenosis affecting kidney graft perfusion: a single-centre study in 53 patients. Am J Transplant 2005; 5:1731.</a></li><li><a class="nounderline abstract_t">Pouria S, State OI, Wong W, Hendry BM. CMV infection is associated with transplant renal artery stenosis. QJM 1998; 91:185.</a></li><li><a class="nounderline abstract_t">Humar A, Matas AJ. Surgical complications after kidney transplantation. Semin Dial 2005; 18:505.</a></li><li><a class="nounderline abstract_t">Cowley AW Jr, Roman RJ. The role of the kidney in hypertension. JAMA 1996; 275:1581.</a></li><li><a class="nounderline abstract_t">Curtis JJ, Luke RG, Dustan HP, et al. Remission of essential hypertension after renal transplantation. N Engl J Med 1983; 309:1009.</a></li><li><a class="nounderline abstract_t">Guidi E, Menghetti D, Milani S, et al. Hypertension may be transplanted with the kidney in humans: a long-term historical prospective follow-up of recipients grafted with kidneys coming from donors with or without hypertension in their families. J Am Soc Nephrol 1996; 7:1131.</a></li><li><a class="nounderline abstract_t">Guidi E, Cozzi MG, Minetti E, Bianchi G. Donor and recipient family histories of hypertension influence renal impairment and blood pressure during acute rejections. J Am Soc Nephrol 1998; 9:2102.</a></li><li><a class="nounderline abstract_t">Mallamaci F, Tripepi R, D'Arrigo G, et al. Long-term blood pressure monitoring by office and 24-h ambulatory blood pressure in renal transplant patients: a longitudinal study. Nephrol Dial Transplant 2019; 34:1558.</a></li><li><a class="nounderline abstract_t">Loubeyre P, Abidi H, Cahen R, Tran Minh VA. Transplanted renal artery: detection of stenosis with color Doppler US. Radiology 1997; 203:661.</a></li><li><a class="nounderline abstract_t">Baxter GM, Ireland H, Moss JG, et al. Colour Doppler ultrasound in renal transplant artery stenosis: which Doppler index? Clin Radiol 1995; 50:618.</a></li><li><a class="nounderline abstract_t">de Morais RH, Muglia VF, Mamere AE, et al. Duplex Doppler sonography of transplant renal artery stenosis. J Clin Ultrasound 2003; 31:135.</a></li><li><a class="nounderline abstract_t">Grenier N, Douws C, Morel D, et al. Detection of vascular complications in renal allografts with color Doppler flow imaging. Radiology 1991; 178:217.</a></li><li><a class="nounderline abstract_t">Glicklich D, Tellis VA, Quinn T, et al. Comparison of captopril scan and Doppler ultrasonography as screening tests for transplant renal artery stenosis. Transplantation 1990; 49:217.</a></li><li><a class="nounderline abstract_t">Malfi B, Ferretti G, Messina M, et al. Echo-Doppler velocimetry in the diagnosis of renal artery stenosis on transplanted kidney. Clin Nephrol 1986; 26:181.</a></li><li><a class="nounderline abstract_t">Snider JF, Hunter DW, Moradian GP, et al. Transplant renal artery stenosis: evaluation with duplex sonography. Radiology 1989; 172:1027.</a></li><li><a class="nounderline abstract_t">Sun IO, Hong YA, Kim HG, et al. Clinical usefulness of 3-dimensional computerized tomographic renal angiography to detect transplant renal artery stenosis. Transplant Proc 2012; 44:691.</a></li><li><a class="nounderline abstract_t">Hofmann LV, Smith PA, Kuszyk BS, et al. Three-dimensional helical CT angiography in renal transplant recipients: a new problem-solving tool. AJR Am J Roentgenol 1999; 173:1085.</a></li><li><a class="nounderline abstract_t">Loubeyre P, Cahen R, Grozel F, et al. Transplant renal artery stenosis. Evaluation of diagnosis with magnetic resonance angiography compared with color duplex sonography and arteriography. Transplantation 1996; 62:446.</a></li><li><a class="nounderline abstract_t">Cahen R, Loubeyre P, Trolliet P, et al. Magnetic resonance angiography for the detection of transplant renal artery stenosis. Transplant Proc 1996; 28:2830.</a></li><li><a class="nounderline abstract_t">Johnson DB, Lerner CA, Prince MR, et al. Gadolinium-enhanced magnetic resonance angiography of renal transplants. Magn Reson Imaging 1997; 15:13.</a></li><li><a class="nounderline abstract_t">Kelekis NL, Semelka RC, Worawattanakul S, et al. Magnetic resonance imaging of the abdominal aorta and iliac vessels using combined 3-D gadolinium-enhanced MRA and gadolinium-enhanced fat-suppressed spoiled gradient echo sequences. Magn Reson Imaging 1999; 17:641.</a></li><li><a class="nounderline abstract_t">Huber A, Heuck A, Scheidler J, et al. Contrast-enhanced MR angiography in patients after kidney transplantation. Eur Radiol 2001; 11:2488.</a></li><li><a class="nounderline abstract_t">Chan YL, Leung CB, Yu SC, et al. Comparison of non-breath-hold high resolution gadolinium-enhanced MRA with digital subtraction angiography in the evaluation on allograft renal artery stenosis. Clin Radiol 2001; 56:127.</a></li><li><a class="nounderline abstract_t">Ferreiros J, Mendez R, Jorquera M, et al. Using gadolinium-enhanced three-dimensional MR angiography to assess arterial inflow stenosis after kidney transplantation. AJR Am J Roentgenol 1999; 172:751.</a></li><li><a class="nounderline abstract_t">Luk SH, Chan JH, Kwan TH, et al. Breath-hold 3D gadolinium-enhanced subtraction MRA in the detection of transplant renal artery stenosis. Clin Radiol 1999; 54:651.</a></li><li><a class="nounderline abstract_t">Sankari BR, Geisinger M, Zelch M, et al. Post-transplant renal artery stenosis: impact of therapy on long-term kidney function and blood pressure control. J Urol 1996; 155:1860.</a></li><li><a class="nounderline abstract_t">Rigatto C, Foley R, Jeffery J, et al. Electrocardiographic left ventricular hypertrophy in renal transplant recipients: prognostic value and impact of blood pressure and anemia. J Am Soc Nephrol 2003; 14:462.</a></li><li><a class="nounderline abstract_t">Hernández D. Left ventricular hypertrophy after renal transplantation: new approach to a deadly disorder. Nephrol Dial Transplant 2004; 19:1682.</a></li><li><a class="nounderline abstract_t">Mange KC, Feldman HI, Joffe MM, et al. Blood pressure and the survival of renal allografts from living donors. J Am Soc Nephrol 2004; 15:187.</a></li><li><a class="nounderline abstract_t">de Vries AP, Bakker SJ, van Son WJ, et al. Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant 2004; 4:1675.</a></li><li><a class="nounderline abstract_t">Fernández-Fresnedo G, Escallada R, Martin de Francisco AL, et al. Association between pulse pressure and cardiovascular disease in renal transplant patients. Am J Transplant 2005; 5:394.</a></li><li><a class="nounderline abstract_t">Sanders CE Jr, Curtis JJ. Role of hypertension in chronic renal allograft dysfunction. Kidney Int Suppl 1995; 52:S43.</a></li><li><a class="nounderline abstract_t">Cheigh JS, Haschemeyer RH, Wang JC, et al. Hypertension in kidney transplant recipients. Effect on long-term renal allograft survival. Am J Hypertens 1989; 2:341.</a></li><li><a class="nounderline abstract_t">Paul LC, Benediktsson H. Post-transplant hypertension and chronic renal allograft failure. Kidney Int Suppl 1995; 52:S34.</a></li><li><a class="nounderline abstract_t">Opelz G, Döhler B, Collaborative Transplant Study. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant 2005; 5:2725.</a></li><li><a class="nounderline abstract_t">Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 Suppl 3:S1.</a></li><li><a class="nounderline abstract_t">Cheung AK, Chang TI, Cushman WC, et al. Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int 2021; 99:559.</a></li><li><a class="nounderline abstract_t">Malhotra R, Katz R, Weiner DE, et al. Blood Pressure, Chronic Kidney Disease Progression, and Kidney Allograft Failure in Kidney Transplant Recipients: A Secondary Analysis of the FAVORIT Trial. Am J Hypertens 2019; 32:816.</a></li><li><a class="nounderline abstract_t">Asai K, Kobayashi T, Miyata H, et al. The Short-Term Impact of Dietary Counseling on Sodium Intake and Blood Pressure in Renal Allograft Recipients. Prog Transplant 2016; 26:365.</a></li><li><a class="nounderline abstract_t">de Vries LV, Dobrowolski LC, van den Bosch JJ, et al. Effects of Dietary Sodium Restriction in Kidney Transplant Recipients Treated With Renin-Angiotensin-Aldosterone System Blockade: A Randomized Clinical Trial. Am J Kidney Dis 2016; 67:936.</a></li><li><a class="nounderline abstract_t">Lafranca JA, IJermans JN, Betjes MG, Dor FJ. Body mass index and outcome in renal transplant recipients: a systematic review and meta-analysis. BMC Med 2015; 13:111.</a></li><li><a class="nounderline abstract_t">Chan G, Garneau P, Hajjar R. The impact and treatment of obesity in kidney transplant candidates and recipients. Can J Kidney Health Dis 2015; 2:26.</a></li><li><a class="nounderline abstract_t">Cross NB, Webster AC, Masson P, et al. Antihypertensive treatment for kidney transplant recipients. Cochrane Database Syst Rev 2009; :CD003598.</a></li><li><a class="nounderline abstract_t">Mourad G, Ribstein J, Mimran A. Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants. Kidney Int 1993; 43:419.</a></li><li><a class="nounderline abstract_t">Ladefoged SD, Pedersen E, Hammer M, et al. Influence of diltiazem on renal function and rejection in renal allograft recipients receiving triple-drug immunosuppression: a randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 1994; 9:543.</a></li><li><a class="nounderline abstract_t">Ladefoged SD, Andersen CB. Calcium channel blockers in kidney transplantation. Clin Transplant 1994; 8:128.</a></li><li><a class="nounderline abstract_t">Midtvedt K, Hartmann A, Foss A, et al. Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril. Transplantation 2001; 72:1787.</a></li><li><a class="nounderline abstract_t">Kuypers DR, Neumayer HH, Fritsche L, et al. Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: a prospective randomized placebo-controlled 2-year study. Transplantation 2004; 78:1204.</a></li><li><a class="nounderline abstract_t">Kovarik JM, Beyer D, Bizot MN, et al. Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. Br J Clin Pharmacol 2005; 60:434.</a></li><li><a class="nounderline abstract_t">Lorenz M, Billensteiner E, Bodingbauer M, et al. The effect of ACE inhibitor and angiotensin II blocker therapy on early posttransplant kidney graft function. Am J Kidney Dis 2004; 43:1065.</a></li><li><a class="nounderline abstract_t">Jennings DL, Taber DJ. Use of renin-angiotensin-aldosterone system inhibitors within the first eight to twelve weeks after renal transplantation. Ann Pharmacother 2008; 42:116.</a></li><li><a class="nounderline abstract_t">Stigant CE, Cohen J, Vivera M, Zaltzman JS. ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy. Am J Kidney Dis 2000; 35:58.</a></li><li><a class="nounderline abstract_t">Holgado R, Anaya F, Del Castillo D. Angiotensin II type 1 (AT1) receptor antagonists in the treatment of hypertension after renal transplantation. Nephrol Dial Transplant 2001; 16 Suppl 1:117.</a></li><li><a class="nounderline abstract_t">Formica RN Jr, Friedman AL, Lorber MI, et al. A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period. Nephrol Dial Transplant 2006; 21:1389.</a></li><li><a class="nounderline abstract_t">Paoletti E, Cassottana P, Amidone M, et al. ACE inhibitors and persistent left ventricular hypertrophy after renal transplantation: a randomized clinical trial. Am J Kidney Dis 2007; 50:133.</a></li><li><a class="nounderline abstract_t">Hiremath S, Fergusson D, Doucette S, et al. Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant 2007; 7:2350.</a></li><li><a class="nounderline abstract_t">Ibrahim HN, Jackson S, Connaire J, et al. Angiotensin II blockade in kidney transplant recipients. J Am Soc Nephrol 2013; 24:320.</a></li><li><a class="nounderline abstract_t">Andrés A, Morales E, Morales JM, et al. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study. Transplant Proc 2006; 38:2419.</a></li><li><a class="nounderline abstract_t">Philipp T, Martinez F, Geiger H, et al. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. Nephrol Dial Transplant 2010; 25:967.</a></li><li><a class="nounderline abstract_t">Suwelack B, Kobelt V, Erfmann M, et al. Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients. Transpl Int 2003; 16:313.</a></li><li><a class="nounderline abstract_t">Pilmore HL, Skeans MA, Snyder JJ, et al. Cardiovascular disease medications after renal transplantation: results from the Patient Outcomes in Renal Transplantation study. Transplantation 2011; 91:542.</a></li><li><a class="nounderline abstract_t">Rizk J, Quan D, Gabardi S, et al. Novel approaches to management of hyperkalaemia in kidney transplantation. Curr Opin Nephrol Hypertens 2021; 30:27.</a></li><li><a class="nounderline abstract_t">Curtis JJ, Luke RG, Diethelm AG, et al. Benefits of removal of native kidneys in hypertension after renal transplantation. Lancet 1985; 2:739.</a></li><li><a class="nounderline abstract_t">Fricke L, Doehn C, Steinhoff J, et al. Treatment of posttransplant hypertension by laparoscopic bilateral nephrectomy? Transplantation 1998; 65:1182.</a></li><li><a class="nounderline abstract_t">Reisfeld D, Matas AJ, Tellis VA, et al. Late follow-up of percutaneous transluminal angioplasty for treatment of transplant renal artery stenosis. Transplant Proc 1989; 21:1955.</a></li><li><a class="nounderline abstract_t">Fervenza FC, Lafayette RA, Alfrey EJ, Petersen J. Renal artery stenosis in kidney transplants. Am J Kidney Dis 1998; 31:142.</a></li><li><a class="nounderline abstract_t">Ruggenenti P, Mosconi L, Bruno S, et al. Post-transplant renal artery stenosis: the hemodynamic response to revascularization. Kidney Int 2001; 60:309.</a></li><li><a class="nounderline abstract_t">Henning BF, Kuchlbauer S, Böger CA, et al. Percutaneous transluminal angioplasty as first-line treatment of transplant renal artery stenosis. Clin Nephrol 2009; 71:543.</a></li><li><a class="nounderline abstract_t">Sierre SD, Raynaud AC, Carreres T, et al. Treatment of recurrent transplant renal artery stenosis with metallic stents. J Vasc Interv Radiol 1998; 9:639.</a></li><li><a class="nounderline abstract_t">Leertouwer TC, Gussenhoven EJ, van Overhagen H, et al. Stent placement for treatment of renal artery stenosis guided by intravascular ultrasound. J Vasc Interv Radiol 1998; 9:945.</a></li><li class="breakAll">Rosenthal, JT. Chapter 7. In: Handbook of kidney transplantation, 2nd ed, Danovitch, GM (Eds), Little, Brown, and Company, Boston 1996. p.130.</li></ol></div><div id="topicVersionRevision">Topic 7360 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15168388" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hypertension after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8494023" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Hypertension after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9122966" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hypertension in patients after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15192139" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Epidemiology of arterial hypertension in renal transplant patients: changes over the last decade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9915263" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Early immunologic and nonimmunologic predictors of arterial hypertension after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18936569" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7967781" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cyclosporine-induced hypertension after transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11888584" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12717205" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8546132" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Endothelin in organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1631945" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7490151" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effects of an endothelin receptor antagonist in rats with cyclosporine-induced hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17595192" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Ciclosporin-induced hypertension is associated with increased sodium transporter of the loop of Henle (NKCC2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21963515" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16433762" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Risk factors and long-term outcome of transplant renal artery stenosis in adult recipients after treatment by percutaneous transluminal angioplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14694165" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Transplant renal artery stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15943633" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Management of arterial stenosis affecting kidney graft perfusion: a single-centre study in 53 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9604070" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : CMV infection is associated with transplant renal artery stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16398714" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Surgical complications after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8622250" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The role of the kidney in hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6353230" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Remission of essential hypertension after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8866403" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Hypertension may be transplanted with the kidney in humans: a long-term historical prospective follow-up of recipients grafted with kidneys coming from donors with or without hypertension in their families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9808097" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Donor and recipient family histories of hypertension influence renal impairment and blood pressure during acute rejections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30476170" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Long-term blood pressure monitoring by office and 24-h ambulatory blood pressure in renal transplant patients: a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9169685" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Transplanted renal artery: detection of stenosis with color Doppler US.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7554736" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Colour Doppler ultrasound in renal transplant artery stenosis: which Doppler index?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12594798" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Duplex Doppler sonography of transplant renal artery stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1984307" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Detection of vascular complications in renal allografts with color Doppler flow imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2405552" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Comparison of captopril scan and Doppler ultrasonography as screening tests for transplant renal artery stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2946501" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Echo-Doppler velocimetry in the diagnosis of renal artery stenosis on transplanted kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2672101" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Transplant renal artery stenosis: evaluation with duplex sonography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22483470" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Clinical usefulness of 3-dimensional computerized tomographic renal angiography to detect transplant renal artery stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10511184" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Three-dimensional helical CT angiography in renal transplant recipients: a new problem-solving tool.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8781608" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Transplant renal artery stenosis. Evaluation of diagnosis with magnetic resonance angiography compared with color duplex sonography and arteriography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8908084" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Magnetic resonance angiography for the detection of transplant renal artery stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9084020" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Gadolinium-enhanced magnetic resonance angiography of renal transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10372517" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Magnetic resonance imaging of the abdominal aorta and iliac vessels using combined 3-D gadolinium-enhanced MRA and gadolinium-enhanced fat-suppressed spoiled gradient echo sequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11734946" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Contrast-enhanced MR angiography in patients after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11222071" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Comparison of non-breath-hold high resolution gadolinium-enhanced MRA with digital subtraction angiography in the evaluation on allograft renal artery stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10063875" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Using gadolinium-enhanced three-dimensional MR angiography to assess arterial inflow stenosis after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10541389" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Breath-hold 3D gadolinium-enhanced subtraction MRA in the detection of transplant renal artery stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8618274" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Post-transplant renal artery stenosis: impact of therapy on long-term kidney function and blood pressure control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12538748" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Electrocardiographic left ventricular hypertrophy in renal transplant recipients: prognostic value and impact of blood pressure and anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15150353" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Left ventricular hypertrophy after renal transplantation: new approach to a deadly disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14694172" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Blood pressure and the survival of renal allografts from living donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15367224" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15644000" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Association between pulse pressure and cardiovascular disease in renal transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8587282" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Role of hypertension in chronic renal allograft dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2655660" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Hypertension in kidney transplant recipients. Effect on long-term renal allograft survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8587280" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Post-transplant hypertension and chronic renal allograft failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16212633" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Improved long-term outcomes after renal transplantation associated with blood pressure control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19845597" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : KDIGO clinical practice guideline for the care of kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33637203" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31179500" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Blood Pressure, Chronic Kidney Disease Progression, and Kidney Allograft Failure in Kidney Transplant Recipients: A Secondary Analysis of the FAVORIT Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27571851" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The Short-Term Impact of Dietary Counseling on Sodium Intake and Blood Pressure in Renal Allograft Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26803690" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Effects of Dietary Sodium Restriction in Kidney Transplant Recipients Treated With Renin-Angiotensin-Aldosterone System Blockade: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25963131" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Body mass index and outcome in renal transplant recipients: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26236496" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The impact and treatment of obesity in kidney transplant candidates and recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19588343" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Antihypertensive treatment for kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8382753" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8090335" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Influence of diltiazem on renal function and rejection in renal allograft recipients receiving triple-drug immunosuppression: a randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8019022" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Calcium channel blockers in kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11740389" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15502721" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: a prospective randomized placebo-controlled 2-year study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16187976" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Pharmacokinetic interaction between verapamil and everolimus in healthy subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15168387" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The effect of ACE inhibitor and angiotensin II blocker therapy on early posttransplant kidney graft function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18094340" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Use of renin-angiotensin-aldosterone system inhibitors within the first eight to twelve weeks after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10620545" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11369838" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Angiotensin II type 1 (AT1) receptor antagonists in the treatment of hypertension after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16431893" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17591533" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : ACE inhibitors and persistent left ventricular hypertrophy after renal transplantation: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17845569" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23308016" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Angiotensin II blockade in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17097955" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19887503" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12759722" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21301401" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Cardiovascular disease medications after renal transplantation: results from the Patient Outcomes in Renal Transplantation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33027094" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Novel approaches to management of hyperkalaemia in kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2864483" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Benefits of removal of native kidneys in hypertension after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9603165" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Treatment of posttransplant hypertension by laparoscopic bilateral nephrectomy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2523597" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Late follow-up of percutaneous transluminal angioplasty for treatment of transplant renal artery stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9428466" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Renal artery stenosis in kidney transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11422766" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Post-transplant renal artery stenosis: the hemodynamic response to revascularization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19473615" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Percutaneous transluminal angioplasty as first-line treatment of transplant renal artery stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9684836" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Treatment of recurrent transplant renal artery stenosis with metallic stents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9840039" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Stent placement for treatment of renal artery stenosis guided by intravascular ultrasound.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
